<DOC>
	<DOCNO>NCT01246427</DOCNO>
	<brief_summary>The purpose study evaluate efficacy homeopathic treatment ( BRN01 ) reduce hot flash score 4 week treatment .</brief_summary>
	<brief_title>Evaluation Homeopathic Treatment Hot Flashes Non Metastatic Breast Cancer</brief_title>
	<detailed_description>Chemotherapy use adjuvant treatment breast cancer , like hormone therapy patient hormone-sensitive breast cancer immunotherapy Human Epidermal growth factor Receptor 2 ( HER2 ) -overexpressing cancer . These adjuvant treatment reduce risk recurrence metastasis . The side effect hormone therapy know depend therapeutic strategy drug use . The side effect Tamoxifen similar menopausal symptom : hot flash ( half female population ) , vaginal dryness leukorrhea , nausea , irregular menstruation , benign ovarian cyst , less frequently , weight gain . Aromatase inhibitor side effect , though less frequency intensity . The incidence rate hot flash adjuvant treatment menopausal woman localize breast cancer 60 65 % , reaction severe one third woman . Despite fact , management hot flash systematic currently therapeutic strategy proven efficiency . BRN01 ( Boiron laboratory ) homeopathic remedy whose active ingredient already present homeopathic drug indicate management menopausal hot flash . BRN01 could reduce intensity reaction woman breast cancer receive adjuvant hormonal treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<criteria>Female patient age ≥ 18 year Women histologically proven non metastatic breast cancer ECOG PS ≤ 1 Patient receive adjuvant hormonal therapy least 1 month ( aromatase inhibitor Tamoxifen ± ovarian function suppression ( Luteinizing Hormone Releasing Hormone agonist ( LHRH agonist ) , ovariectomy ... ) ) Patient complain hot flash moderate severe intensity , affect quality life , least 1 month inclusion Patient agreement start another hot flash treatment study ( allopathic treatment , E vitamin , dietary supplement , phytotherapy , acupuncture ... ) Patient able understand , read write French Mandatory affiliation health insurance system Signed , write informed consent Ongoing chemotherapy radiotherapy , treatment plan begin study Patient condition know induce hot flash hyperthyroidism , diabetes , adrenal tumor , enteric carcinoid tumor , mastocytosis ... Patient severe renal failure , severe hepatic failure , cardiovascular disease Patient one follow contraindication : know hypersensitivity one component study drug galactose , fructose intolerance Lapp lactase deficiency , isomaltase invertase deficiency Glucose galactose malabsorption syndrome Follow impossible social , familial , geographical psychological reason Patient suspect poor compliance protocol treatment Participation another biomedical research trial indication , administration experimental drug indication 30 day inclusion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Adjuvant hormonal therapy</keyword>
	<keyword>Homeopathic treatment</keyword>
	<keyword>Hot flash</keyword>
	<keyword>Quality life</keyword>
	<keyword>Hot flash score</keyword>
</DOC>